AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04623255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCTAPLAS
Description: plasma exchange
Study NCT00776490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 1mg Tablets
Study NCT00776490 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 1mg Tablets
Study NCT01998113 — intervention group
Intervention type: DRUG
Intervention: Glyburide vs Insulin trials
Description: Affecting groups 1 and 2
Study NCT01998113 — intervention group
Intervention type: DRUG
Intervention: Metformin vs Insulin trials
Description: Affecting groups 3 and 4
Study NCT01998113 — intervention group
Intervention type: DRUG
Intervention: Metformin vs Glyburide trials
Description: Affecting groups 5 and 6
Study NCT03423615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Health & Hygiene Improvement Program (CHHIP)
Description: CHHIP is an intense, multi-component holistic school health program based on the WHO Health Promoting School framework and designed for implementation by lay fieldworkers.
Study NCT00537303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)
Study NCT00537303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)
Study NCT00537303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Administered 1 - 3 times daily, at largest prandial increment, injection s.c. (under the skin)
Study NCT00537303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Administered 1 - 3 times daily, at largest meals, injection s.c. (under the skin)
Study NCT01915706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ripcord removal
Description: Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3. Ripcord removal will be performed by study PI at the slit lamp with standard of care sterile technique and topical/local anesthesia. Patients will be monitored 30 minutes following ripcord removal for intraocular pressure as well as complications.
Study NCT05783830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACD856
Description: IV injection 100 mcg
Study NCT03186781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUNPF081-00-VP (HA-F A/Sing)
Description: VRC-FLUNPF081-00-VP (HA-F A/Sing) is an investigational influenza HA ferritin vaccine.
Study NCT03186781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-FLUDNA082-00-VP (DNA A/Sing)
Description: VRC-FLUDNA082-00-VP (DNA A/Sing) is an investigational influenza plasmid DNA vaccine.
Study NCT03203564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modufolin (arfolitixorin)
Description: Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
Study NCT03203564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modufolin (arfolitixorin)
Description: Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
Study NCT03173430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab (Blincyto), an anti-CD19/anti-CD3 bi-specific T cell engager
Study NCT02866006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVAC-C
Description: Autologous B cells and monocytes transfected with E6E7 gene of HPV
Study NCT02866006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Study NCT03648853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetanic Stimulus
Description: 5 second 100 Hz 70 mA tetanic stimulus will be applied to three different locations in a random order
Study NCT03017703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Study NCT04116762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TissuePatchDS-P™
Description: The therapy to be used in the intervention arm is TissuePatchDS-P™. This is a preformed, standard-sized artificial adhesive that will be used between the parotid tissue and subcutaneous tissue. It can be cut to an appropriate size for the defect. The intention of this installation is to seal and close the potential space that is created with removal of superficial parotid tissue
Study NCT04116762 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Drain
Description: A surgical drain used in superficial parotid surgery is a thin polyvinylchloride (PVC) tube, with perforations at the end, which is placed at the end of the procedure before the surgical wound is closed in the cavity created following removal of parotid tissue. The tube is connected to a closed vacuum system attached to a plastic bottle outside of the patient's body which acts to remove the fluid that collects after an operation.
Study NCT01759732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40mg/M2 once daily IV on days -7 to -4
Study NCT01759732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg IV on day-3 and -2
Study NCT01759732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study NCT01759732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT01759732 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy per day on D-5 \& -4
Study NCT01759732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD3-depleted hematopoietic cell transplantation
Description: Immunogenetic depletion on CliniMACS
Study NCT04283201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Moderate activity 150 min per week
Study NCT04283201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macronutrient modification
Description: Insoluble dietary fiber 15 g per day (Vitacel wheat fiber); sugar limitation
Study NCT01778686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram and Pindolol
Description: Citalopram: selective serotonin reuptake inhibitor~Pindolol: non-selective beta blocker and 5-HT1A receptor antagonist
Study NCT01778686 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the second PET scanning day, subjects received a protein drink as well as a 50 ml saline infusion over 1 hour starting 30 min before PET scanning.
Study NCT01778686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Study NCT02958085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: Doses of NNC0174-0833, dosed either once daily or once weekly
Study NCT02958085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosed either once daily or once weekly
Study NCT02353338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Description: Surgical management of radial fracture
Study NCT02974621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT02974621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Given PO
Study NCT02974621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO
Study NCT02974621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT04629352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum Accelerated Transcranial Direct Current Stimulation (acctDCS)
Description: In verum transcranial direct current stimulation (tDCS), patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. For Verum-tDCS condition, 2-mA of constant current will be delivered for 20-minutes, additional ramp-up and ramp-down of 20 seconds each.
Study NCT04629352 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Accelerated Transcranial Direct Current Stimulation (acctDCS)
Description: In sham transcranial direct current stimulation (tDCS), each SCZ patient will receive five sessions daily for two days, a 10-session course of tDCS \[anode: left-DLPFC (at F3) and cathode: left-TPJ (midway between C3 and P3); electrode size: 35cm2\]. However, no current will be delivered beyond initial ramp-up time though the tDCS device display will indicate that 2mA current is being applied.
Study NCT04946188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opuz NICGM
Description: A wearable and non-invasive prototype device that allows for measurement of bioimpedance data with the aim to help develop a mathematical model to predict blood glucose levels.
Study NCT04229563 — intervention group
Intervention type: DEVICE
Intervention: AURYON™ System
Description: The AURYON™ System consists of two sub-units: 1) a single use catheter (AURYON™ catheter); and 2) a laser system.
Study NCT01796080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mueller manoeuvre
Study NCT01796080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory threshold
Study NCT01796080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory apnoea
Study NCT02705820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Switch maintenance pembrolizumab treatment
Study NCT02353338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative management
Description: Immobilized/cast for 6 weeks
Study NCT02353338 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cast
Study NCT03781388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Determination of the dose will rely on the outcomes of the preceding 7 patients receiving the same dose, as the number of previous patients to consider is a function of the target dose. Among all patients who received a certain dose, a proportion of successful outcomes will be determined (P(d)); if P(d) \<0.90, and at least one of the previous 7 patients who received the same dose had an unsatisfactory outcome, the next patient will receive a pre-determined increment of 0.75 mg of bupivacaine. Alternatively, if P(d) 0.90 and the previous 7 patients who received the same dose had successful outcomes, the next patient will receive a pre-determined decrement of 0.75mg of bupivacaine. Otherwise, the dose will remain the same.
Study NCT01351857 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Transition Coordinator
Description: The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
Study NCT04125381 — intervention group
Intervention type: OTHER
Intervention: Exposure to Arsenic by drinking water
Description: People residing in municipalities with Arsenic drinking water concentrations over legal threshold (10 µg/L), were considered as exposed.
Study NCT00427791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 60 mg/kg IV Daily Over 4 Hours for 1 Day
Study NCT00427791 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 3 Gy Daily for 4 Days
Study NCT00427791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV Weekly Over 4-8 Hours for 4 Weeks
Study NCT04776889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Description: Rosuvastatin 20mg/day for 6 months added to bilateral subcapsular orchiectomy
Study NCT04776889 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical castration
Description: bilateral subcapsular orchiectomy
Study NCT02454452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
Study NCT02454452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saphenous vein stripping
Description: Saphenous vein stripping
Study NCT02454452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CHIVA
Description: conservative hemodynamic treatment venous insufficiency
Study NCT03889990 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IQOS
Description: Smoke IQOS
Study NCT01855425 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: Subjects to receive standard of care CT scan and additional Cone Beam CT scan.
Study NCT01924195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anlotinib
Description: Anlotinib QD po.
Study NCT01924195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo QD po.
Study NCT02422394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Study NCT02348294 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Shear- force 19 newton and 3,9 kpa pressure for half an hour
Study NCT01796080 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Steady state normal breathing
Study NCT01784159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin administration for 7 days
Study NCT01784159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin administration for 7 days
Study NCT01558271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Study NCT01558271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2189265
Study NCT01558271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01611922 — intervention group
Intervention type: OTHER
Intervention: Ophthalmic dye
Description: Topically instilled for the purpose of assessing lid margin staining
Study NCT01611922 — intervention group
Intervention type: DEVICE
Intervention: Contact lenses
Description: Silicone hydrogel contact lenses per subject's habitual brand and power, worn for a minimum of 8 hours on the day of assessment, after which lenses will be removed and dye will be instilled.
Study NCT03187535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS via ES-130
Description: Transcutaneous Electrical Acupoint Stimulation will be administered delivered by the ES-130 device for 20 minutes at the time ondansetron is given (typically 30 minutes before the end of surgery). Subjects randomized to this intervention will have the TEAS device connected to the previously placed ECG patches to deliver the stimulus.
Study NCT03187535 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No TEAS
Description: No Transcutaneous Electrical Acupoint Stimulation will be delivered to the subjects randomized to this group; ECG patches will be placed at the identified acupoints, however, no electrical stimulus will be delivered.
Study NCT03496662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-813160
Description: BMS-813160 will be supplied by Bristol Myers Squibb
Study NCT03496662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be supplied by Bristol Myers Squibb
Study NCT03496662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be given as per routine care from commercial supply.
Study NCT03496662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be given as per routine care from commercial supply.
Study NCT03496662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be given as per routine care from commercial supply.
Study NCT03496662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel will be given as per routine care from commercial supply.
Study NCT03496662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Pre-treatment, end of cycle 2, end of treatment for patients who progress or otherwise do not go to surgery, and surgery for patients who do go to surgery
Study NCT03496662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Pre-treatment, end of cycle 2, end of treatment for patients who progress or otherwise do not go to surgery, and surgery for patients who do go to surgery
Study NCT03496662 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral blood
Description: -Cycle 1 Day 1 before treatment begins, after 2 cycles of treatment +/- 3 days of mandatory tumor biopsy, end of treatment for patients who progress or otherwise do not go to surgery, and no more than 24 hours prior to time of surgery (if applicable)
Study NCT03496662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: -Cycle 1 Day 1 before treatment begins, after 2 cycles of treatment +/- 3 days of mandatory tumor biopsy, end of treatment for patients who progress or otherwise do not go to surgery, and no more than 24 hours prior to time of surgery (if applicable)
Study NCT01301417 — intervention group
Intervention type: DEVICE
Intervention: ColonRing™
Description: Creation of a circular Compression Anastomosis
Study NCT01407289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart, Insulin Glargine
Description: The Intervention is a paper based protocol, which provides suggestions for new insulin doses (basal-bolus regime).
Study NCT01558271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Study NCT01775085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: manualized group intervention
Description: MCG-BCS manual outlines 8 approximately, 90-minute modules: 1) Concepts \& Sources of Meaning; 2) Identity, Cancer Survivorship, \& Meaning; 3) Historical Sources of Meaning: Past Legacy; 4) Historical Sources of Meaning: Present \& Future Legacy; 5) Attitudinal Sources of Meaning: Encountering Life's Limitations; 6) Creative Sources of Meaning: Creativity \& Responsibility; 7) Experiential Sources of Meaning: Connecting with Life via Love, Beauty, \& Humor; and 8) Transitions: Reflections \& Hopes for the Future.
Study NCT01775085 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standardized, manualized group intervention
Description: DG is a standardized, manualized group developed by the MSKCC Psychiatry Service and utilized in a similar form in our completed and ongoing RCTs of MCGP. Based on models described by Rogers and Bloch, the essential components include reassurance, explanation, education, encouragement, and permission for expression. The process emphasizes Rogerian concepts (e.g., empathic understanding) and avoids techniques that are not exclusively supportive. The content focuses on education about here-and-now topics relevant to BCS (e.g., maintaining and eliciting social support, financial strains, return to work, physical symptom management), allowing emotional expression and discussion of difficult topics.
Study NCT02225925 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Study NCT00558740 — intervention group
Intervention type: OTHER
Intervention: high protein intake
Description: acute high protein intake chronic (6-day) high protein intake acute+chronic high protein intake control
Study NCT03925883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient navigation
Description: Receive up to 6 live phone calls with a patient navigator for education, barrier assessment, and barrier resolution to follow up colonoscopy
Study NCT03209596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice (1L/d)
Description: The players (n=17) drank 1 liter per day of orange juice. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
Study NCT03209596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control drink (1L/d)
Description: The players (n=13) drank 1 liter per day of the control drink during a 60-day period. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
Study NCT00779285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
Study NCT02703662 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice biologic mesh
Description: Patients randomized to this group will be inserted one or more Strattice biologic meshes during the abdominal wall reconstruction surgical procedure.